Table 2.
Base-case and scenario analyses results
| Treatment | Cost ($) | ∆Cost | QALYs | ∆QALYs | ICER |
| Base-case | |||||
| LEN-TACE | 31 394 | 12 151 | 1.166 | 0.382 | 31 808 |
| LEN | 19 243 | NA | 0.784 | NA | NA |
| Scenario | |||||
| Weibull model | |||||
| LEN-TACE | 30 629 | 11 736 | 1.072 | 0.328 | 35 780 |
| LEN | 18 893 | NA | 0.744 | NA | NA |
| Royston/Parmar spline model | |||||
| LEN-TACE | 31 468 | 10 733 | 1.203 | 0.320 | 33 540 |
| LEN | 20 735 | NA | 0.883 | NA | NA |
ICER, incremental cost-effectiveness ratio; LEN, lenvatinib; NA, not applicable; QALYs, quality-adjusted life years; TACE, transarterial chemoembolisation.